Login to Your Account



‘Big win’ for Mylan as generic Copaxone gets unexpected FDA nod

By Jennifer Boggs
Managing Editor

Wednesday, October 4, 2017

In a move that caught many by surprise, the FDA late Tuesday approved Mylan NV’s generic version of Copaxone (glatiramer acetate injection), both the 40-mg and 20-mg formulations, sending shares of Mylan up 16 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription